n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, November 16th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Creative Medical Technology Holdings, Inc. (CELZ)

OTC Markets and MarketWatch reported on Creative Medical Technology Holdings, Inc. (CELZ), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (CMT) is a clinical stage stem cell company. Its focus is on Urology and Neurology utilizing stem cell treatments. CMT and its affiliate company, Creative Medical Health, Inc., have concentrated on regenerative medical solutions for unmet Urological and Neurological needs since 2011. The Company has a patent portfolio covering all treatments. CMT has its headquarters in Phoenix, Arizona.

The Company (via its own research and also collaborations with leading academic institutions) has acquired a pioneering stem cell (Amniostem), and developed proprietary protocols. It has also built an extensive intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA. Moreover, CMT is making advances for treating stroke employing its newly acquired amniotic fluid-based stem cell.

Amniostem is Amniotic fluid derived stem cell. The Amniostem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable way. Amniostem therapy is a practical protocol for producing therapeutic quality stem cells starting from a small (1-5 ml) amniocentesis sample. Amniostem cells do not require matching with the recipient, as one size fits all.

CMT has its StemSpine™ initiative. This is a treatment designed to reverse the affects of atherosclerosis, which is the underlying disease that causes disc degeneration. CMT’s solutions include Caverstem™ for Erectile Dysfunction (ED).

The Company has an exclusive rights agreement with UCLA for US patent application # 14/508763, encompassing the use of stem cells for the treatment of male infertility. Additionally, CMT has filed US patent application number #62319753, covering the treatment of female sexual dysfunction utilizing stem cell and progenitor cell populations.

CMT announced in July 2017 preclinical data showing exosomes harvested from its patented Amniostem amniotic fluid stem cell, selectively inhibit growth of glioma brain cancer cells.  Exosomes are nanoparticles generated by a variety of cells that are critically involved in intercellular communication. CMT earlier filed patents on the use of Amniostem derived exosomes for the treatment of stroke.

Last month, CMT announced the filing of a patent application utilizing a combination of a Food and Drug Administration (FDA) approved drug together with the patient's own bone marrow derived stem cells for the treatment of stroke. The patent, entitled "Autologous Bone Marrow Mononuclear Cells as a Substrate for Enhancement of Neuroregenerative Therapy", encompasses the use of the patient's bone marrow stem cells, together with an FDA approved drug, to stimulate the naturally occurring regenerative processes after certain kinds of strokes.

At present, CMT has two issued patents using the patient's own bone marrow stem cells covering disc regeneration #9,598,673, and erectile dysfunction #8,372,797. CMT recently reported completion of enrolment in its clinical trial for erectile dysfunction.

In addition, last month, CMT announced completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem™ procedure. The trial was sponsored by CMT.

The trial was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval. Furthermore, an independent medical safety monitor was appointed to review the patient data for safety and feasibility of administering bone marrow derived stem cells into patients with erectile dysfunction.

Creative Medical Technology Holdings, Inc. (CELZ), closed Thursday's trading session at $0.0485, down 19.17%, on 6,400 volume with 3 trades. The average volume for the last 60 days is 8,094 and the stock's 52-week low/high is $0.035/$0.70.

MassRoots, Inc. (MSRT)

SmallCapVoice, Penny Stock 101, Money Morning, Stock News Now, OTCtipReporter, StockRockandRoll, SeeThruEquity Research, Damn Good Penny Picks, Penny Picks, CFN Media Group, Wealth Daily, Cannabis Financial Network News, Equities, The Street, Promotion Stock Secrets, PennyStockLocks, PennyStockScholar, Profitable Trader Authority, Stock Commander, and OTCJournal reported on MassRoots, Inc. (MSRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MassRoots, Inc. is a leading technology platform for medical cannabis patients and businesses. Individuals use its application to share their cannabis experiences and stay connected with local dispensaries. MassRoots has affiliations with the foremost organizations in the cannabis industry. These include the ArcView Group and the National Cannabis Industry Association. MassRoots has its corporate office in Denver, Colorado.

Businesses can use MassRoots to advertise their goods and services to cannabis consumers. MassRoots starts adding in features. These include order ahead, delivery, and the in-app purchase of ancillary products as regulations permit. Cannabis enthusiasts collectively engage greater than 300,000 times per day on MassRoots’ network. The Company’s plan is to expand to numerous states.

MassRoots has some estimated 300-plus dispensaries actively posting on its network. These include the nation's top dispensaries: Native Roots, MiNDFUL, The Clinic, BuddyBoyBrands, Green Solution, Good Chemistry, Denver Relief, Natural Remedies, and Harborside Health Center.

MassRoots’ product pipeline includes Dispensary Finder & Menus; Product Pages & Reviews; Sponsored Posts 2.0; and Enhanced Profiles. The majority of the Company’s advertising revenue has come from dispensaries and cannabis-brands in the States of California and Colorado.

MassRoots completed its acquisition of DDDigtal, d.b.a. "Whaxy" in January 2017. This is an online order-ahead and menu management platform. This past June, MassRoots and HIGH TIMES announced that MassRoots made a strategic investment in High Times Holding Corporation, "High Times", the leading voice of the Cannabis Industry, in February 2017.

HIGH TIMES is the world's leading cannabis media, events, and information business. As disclosed in MassRoots' Quarterly Report on Form 10-Q filed on May 22, 2017, MassRoots made the strategic equity investment in High Times Holdings Corporation.

This past July, MassRoots announced it closed the acquisition of Odava, Inc. for cash and common stock consideration. MassRoots now offers dispensaries a total set of software to manage their regulatory compliance, streamline their supply chain, and develop successful consumer loyalty programs. Odava is a foremost compliance and point-of-sale (POS) system for the cannabis industry.

Subsequently, in August, MassRoots announced the acquisition of CannaRegs, Inc. MassRoots entered into a definitive agreement to acquire CannaRegs in a stock deal valued at roughly $12 million. CannaRegs is a leading technology platform. It tracks changes in cannabis regulations and taxation at the municipal, state, as well as federal levels.

Recently, MassRoots announced the release of its new Dispensary Finder service with 6,000 entries that catalogue all medical, recreational, and delivery-based dispensaries in nine States. The Company launched its Dispensary Finder service together with Sweet Leaf, a top medical and recreational dispensary chain with more than 20 locations in Colorado, California, and Oregon with headquarters in Denver, Colorado, as Dispensary Finder's first promoted customer.

The 6,000 entries available at launch include all dispensaries in Washington, Oregon, California, Arizona, Colorado, Wisconsin, Michigan, New Hampshire and Massachusetts. The expectation is that more States will come on board by the end of 2017.

MassRoots, Inc. (MSRT), closed Thursday's trading session at $0.1565, up 5.74%, on 907,484 volume with 221 trades. The average volume for the last 60 days is 932,897 and the stock's 52-week low/high is $0.1156/$1.18.

Yew Bio-Pharm Group, Inc. (YEWB)

Greenbackers reported earlier on Yew Bio-Pharm Group, Inc. (YEWB), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Yew Bio-Pharm Group, Inc., by way of its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM), handicraft products made from yew timber, and yew candle and soap made with yew essence oil in China.

The Company uses a patented, accelerated growth technology to expedite the growth and maturity and commercialization of yew trees. In addition, Yew Bio-Pharm has created a division to concentrate on organic foods and dietary supplements. Its aim is to develop new business opportunities in related industries.

Established in 1996, Yew Bio-Pharm is based in Xiangfang District, Harbin City, Heilongjiang Province, China. The Company lists on the OTC Markets Group’s OTCQB.

Yew Bio-Pharm also operates production facilities to manufacture yew handicrafts. The Company’s patented Asexual Reproduction Method speeds up the commercial viability of a yew tree. As a result, a yew tree can be used for commercialization beginning in about three years, in comparison to more than 50 years for naturally grown yew trees.

Via this method, Yew Bio-Pharm can more than replenish the number of yew trees it cultivates and puts into production. The patented Asexual Reproduction Method  was developed by Yew Bio-Pharm’s Founder and President, Mr. Zhiguo Wang. The Patent is valid through September 29, 2030.

Yew Bio-Pharm grows Japanese yew trees (also known in China as Northeast yew trees), taxus cuspidata, on mountain hillsides near Harbin. It cultivates them in four nurseries it operates close to Harbin.

Raw material from the species of yew tree that the Company grows contains taxol. Also, TCM containing yew raw materials has received approval as a traditional Chinese medicine (TCM) in China for the secondary treatment of certain cancers.

This week, Yew Bio-Pharm Group reported financial results for the three- and nine-months ended September 30, 2017. Concerning Q3, Total Revenues for Q3 of 2017 decreased 21.2 percent to $11.6 million from $14.7 million the year prior.

Sales of TCM raw materials were 25.4 percent of Total Revenues. Sales of yew trees amounted to 0 percent of Total Revenues. Sales of handicrafts were 0 percent of Total Revenues. In addition, sales of others, primarily comprising yew candles, pine needle extract, and essential oil soaps were 74.6 percent of Total Revenues.

Net Income for the three months ended September 30, 2017 decreased 43.1 percent to $614,407 from $1.1 million in the same quarter the year prior. Earnings per diluted share for the three months ended September 30, 2017 was $0.01, versus $0.02 for the same quarter of the year prior.

Regarding the nine months of 2017, Net Income grew 221.2 percent to $11.0 million from $3.4 million for the same period last year. Earnings per diluted share were $0.20, versus $0.07 for the same period last year.

Yew Bio-Pharm Group, Inc. (YEWB), closed Thursday's trading session at $0.26965, down 3.70%, on 2,500 volume with 1 trade. The average volume for the last 60 days is 6,710 and the stock's 52-week low/high is $0.1511/$0.4699.

BioVie, Inc. (BIVI)

Wealth Insider Alert reported earlier on BioVie, Inc. (BIVI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. concentrates on the discovery, development, and commercialization of unique drug therapies for liver disease. At present, the clinical-stage company is centering on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. Listed on the OTC Markets’ OTCQB, BioVie is based in Beverly, Massachusetts.

Late in 2016, the Company submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for BIV201. It said it was waiting on clearance to begin a clinical trial program. BioVie said that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis because of hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering BioVie’s new drug candidate BIV201.

BIV201 is a continuous infusion of the peptide terlipressin, initially undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in about 40 countries for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the U.S.

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. In addition to patient suffering, U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion per annum.

BioVie announced in February 2017 that it submitted a complete response to the FDA addressing the issues identified in the Investigational New Drug Application (IND) clinical hold letter received by the Company in January 2017.

BioVie announced on April 3, 2017, that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 may start. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis.

BioVie was also notified by the USPTO that its application for a core patent covering the use of BIV201 to reduce ascites formation in ambulatory patients was authorized.

BioVie also announced this past April the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis.

This past summer, BioVie announced the filing of an application in Japan for patent coverage of its BIV201 for the treatment of ascites in patients with advanced liver cirrhosis. BioVie is pursuing an approach known as the "patent prosecution highway" to seek an accelerated patent approval in Japan that may take less than one year.

Last week, BioVie reported that a second patient was dosed with the Orphan drug candidate BIV201 (continuous infusion terlipressin) in a mid-stage Phase 2a clinical trial of patients suffering from refractory ascites because of advanced liver cirrhosis. The design of the study is to evaluate 6 patients with refractory ascites. In October, the first patient completed 28 days of treatment with BIV201 and entered the post-therapy observational period.

BioVie, Inc. (BIVI), closed Thursday's trading session at $0.21, down 12.50%, on 5,897 volume with 3 trades. The average volume for the last 60 days is 10,008 and the stock's 52-week low/high is $0.1556/$0.45.

Strategic Environmental & Energy Resources, Inc. (SENR)

Marketbeat and Streetwise Reports reported on Strategic Environmental & Energy Resources, Inc. (SENR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Strategic Environmental & Energy Resources, Inc. (SENR) is a provider of environmental, renewable fuels and industrial waste stream management services. The Company has three wholly-owned operating subsidiaries. These are REGS, LLC; MV Technologies, LLC, and SEER Environmental Materials, LLC. SENR works for either destroying/minimizing hazardous waste streams more safely and at lesser cost than any competitive alternative, and/or processing the waste for use as a renewable fuel for the benefit of customers and the environment. OTCQB-listed, the Company is headquartered in Golden, Colorado.

SENR also has two majority-owned subsidiaries. These are Paragon Waste Solutions, LLC; and ReaCH4biogas (Reach). In essence, SENR identifies, secures, and commercializes patented and proprietary environmental clean technologies in a number of multibillion dollar sectors. These sectors include oil & gas, renewable fuels, and all kinds of waste management, solid and gaseous.

The Company provides environmental, renewable fuels, and industrial waste stream management services to oil producers and refiners, railcar operators, industrial and manufacturing companies, medical facilities, government agencies, universities and environmental consulting firms. Its customers engage the Company to manage initiatives ranging from improving operating efficiencies to EPA (Environmental Protection Agency) compliance to creation of renewable fuels.

Concerning Odor/Emissions Control & Renewable Fuels, the Company’s MV Technologies is an engineering/technology enterprise. MV designs and provides odor, vapor, as well as emission control systems for different sectors.

Regarding Industrial/Environmental solutions, SENR’s solutions portfolio includes services for environmental regulation and compliance, upstream/downstream oil and gas operations, wastewater treatment, dewatering/centrifuging, railcar and tank cleaning, and general waste handling and minimization services.

Pertaining to Waste Destruction, SENR’s Paragon Waste Solutions is at the technological vanguard of the waste management and destruction industry. Paragon Waste Solutions’ patent-pending CoronaLux™ system utilizes a low-energy, plasma-enhanced pyrolytic process to safely and reliably destroy hazardous, chemical, biological (military de-weaponization), pharmaceutical, and regulated medical waste.

This past August, SENR (as part of its strategic shift to a dedicated environmental technology company) announced it completed the sale of its wholly-owned railcar cleaning division, Tactical Cleaning Company, LLC to Tactical Cleaning Acquisition LLC, an affiliate of New Seneca Partners. The Company received $2.4 million at the close on July 31, 2017. It will receive guaranteed payments of $1.1 million over the next three years.

SENR is also entitled to receive another $1.5 million based on Tactical's performance, also over the next three years. The sale contract represents a total possible purchase price of $5.0 million. SENR’s expectation is to use the net proceeds from the sale for general corporate purposes, repayment of debt obligations, as well as growth opportunities in its core businesses.

This week, SENR reported financial results for its Q3 ended September 30, 2017. The Company’s Chief Executive Officer, Mr. John Combs, said, “Now that the Tactical sale has been finalized, our strategy is to focus on and accelerate our near-term expansion goals for the technology divisions. Specifically, we plan to ramp Paragon's medical waste destruction technology and focus on increasing MV's market share in the landfill gas sector. We anticipate that these opportunities will enable us to expeditiously achieve our goals and ultimately increase shareholder value."

Strategic Environmental & Energy Resources, Inc. (SENR), closed Thursday's trading session at $0.47, down 7.83%, on 46,725 volume with 34 trades. The average volume for the last 60 days is 21,849 and the stock's 52-week low/high is $0.44/$1.08.

Provectus Biopharmaceuticals, Inc. (PVCT)

StreetAuthorityDaily, TheMicrocapNews, Streetwise Reports, AllPennyStocks, Stock News Now, Seeking Alpha, TopPennyStockMovers, StreetInsider, The Street, TopStockAnalysts, plrinvest, Investors Underground, Real Pennies, PennyStocks24, Club Penny Stocks Network, and Wise Alerts reported previously on Provectus Biopharmaceuticals, Inc. (PVCT), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Provectus Biopharmaceuticals, Inc. is a clinical-stage oncology and dermatology biopharmaceutical company. It is developing new therapies for the treatment of solid tumor cancers and dermatologic diseases. The Company’s investigational oncology drug is PV-10. PV-10 is an oncolytic immunotherapy enrolling patients in Phase 3 clinical trials for metastatic melanoma. Provectus Biopharmaceuticals is based in Knoxville, Tennessee.

PV-10 is an ablative immunotherapy under investigation in solid tumor cancers. PH-10 is a topical investigational drug for dermatology. It is undergoing clinical testing for psoriasis and atopic dermatitis.

Provectus Pharmaceuticals completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. The intention of PV-10 is to kill only diseased cells upon injection into tumors. The Company has received orphan drug designations from the Food and Drug Administration (FDA) for its melanoma and hepatocellular carcinoma indications.

PV-10 is a 10 percent solution of small molecule and halogenated xanthene Rose Bengal. It is administered by way of direct injection into solid tumor cancers, such as melanoma, liver, and breast. It is not designed to rely on a single pathway, receptor or antigen to work; and there is no known resistance.

Pertaining to PH-10 for psoriasis and atopic dermatitis, a mechanism of action study is underway to measure the clinical and cellular response to PH-10's active investigational agent. A total of 226 subjects have been treated with PH-10 in Phase 1 or Phase 2 Clinical Trials.

Last week, Provectus Biopharmaceuticals announced that results from its continuing Phase 1b/2 study of IL PV-10 in combination with KEYTRUDA® (pembrolizumab), Merck’s systemic anti-PD-1 (programmed death receptor-1) antibody agent, were presented at the Society for Melanoma Research 2017 Congress, which took place in Brisbane, Australia from October 18-21.

IL injection of PV-10 induces immunogenic cell death that results in tumor-specific reactivity in circulating CD8+ T cells. There was a 50 percent overall objective response rate; 10 percent complete response. Adverse events were consistent with established patterns for each drug, and no unexpected toxicities were observed.

This week, Provectus Biopharmaceuticals announced that results from a Provectus-sponsored study to understand the daily life experiences of patients with locally advanced cutaneous melanoma were presented at the International Society for Quality of Life Research (ISOQOL) 24th Annual Conference in Philadelphia, Pennsylvania from October 18-21, 2017. Patient perceptions of their experiences related to this kind of melanoma are not well understood.

Mr. Dominic Rodrigues, Chairman of Provectus Pharmaceuticals’ Board of Directors, said, “These elicitation study data of patient-reported assessments of disease symptoms and quality of life show that patients afflicted with locally advanced cutaneous melanoma suffer important emotional impacts, presumably because they see their disease on a continuous basis. Intralesional therapy in general, and intralesional PV-10 in particular, may shrink or eliminate these patients’ accessible and visible tumors.

Provectus Biopharmaceuticals, Inc. (PVCT), closed Thursday's trading session at $0.039, up 1.83%, on 251,178 volume with 23 trades. The average volume for the last 60 days is 558,480 and the stock's 52-week low/high is $0.011/$0.0679.

SNAP Interactive, Inc. (STVI)

SmallCapVoice, PennyTrader Publisher, Global Equity Report, BullRally, CoolPennyStocks, HotOTC, Penny Invest, Stock Rich, Marketbeat, Greenbackers, TopPennyStockMovers, SmarTrend Newsletters, FeedBlitz, StockEgg, OTC Picks, Market Wrap Daily and Stock Traders Chat reported on SNAP Interactive, Inc. (STVI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

SNAP Interactive, Inc. develops, owns and operates dating applications for social networking websites and mobile platforms. It provides online dating applications under the FirstMet and The Grade brands in the U.S. The SNAP product portfolio additionally includes Paltalk and Camfrog that together host one of the world's largest collections of video-based communities. SNAP Interactive is headquartered in New York, New York.

The Company’s flagship brand is FirstMet. FirstMet reflects SNAP Interactive’s vision for making it easier for single adults to meet new people in a friendly, low-pressure environment. FirstMet is a prominent interactive dating brand serving users 35 and older. It is a multi-platform online dating site with a large user database.

The FirstMet brand is fully integrated across Facebook, iPhone, Android, and the Worldwide Web. FirstMet is one of the first dating apps to integrate with Facebook.

SNAP Interactive’s “The Grade” is a mobile dating application catering to high-quality singles. The Grade holds users accountable for their behavior through employing a proprietary algorithm. The algorithm assigns letter grades to users ranging from "A+" to "F" based on profile quality, responsiveness, and peer-reviews generated from the opinions received from other users. Users with a grade of "D" or "F" receive a warning and instructions on how to improve their grade. Users who maintain an "F" grade are expelled.

In addition, SNAP has its “Tinychat.” This is an online video chat community. Tinychat is available on PC, Mac, iOS, Android, and tablet.

Earlier in November, Snap Interactive announced the launch of a one-to-many live streaming video capability as an enhancement to Camfrog. Camfrog has developed to include Camfrog Live within the existing platform. Camfrog Live extends the range of content available to Camfrog users through creating a platform for amateur and established live video content creators.

Camfrog Live provides each content creator his or her own live channel. In addition, it equips them with monetization tools and revenue share eligibility. Camfrog is a cross-platform global video chat community. It has millions of active users in thousands of video chat rooms.

Last week, Snap Interactive announced a multipoint strategy to incorporate the growth potential and technological capabilities of blockchain technology. SNAP has already started to take advantage of key elements of blockchain and cryptocurrency into its product family. The Company envisions utilizing its expertise to build a Blockchain Platform strategy, with an emphasis on promoting next generation social applications leveraging blockchain and cryptocurrency tokens through internal development, partnerships, and investments.

SNAP Interactive, Inc. (STVI), closed Thursday's trading session at $1.80, down 5.26%, on 400 volume with 3 trades. The average volume for the last 60 days is 2,091 and the stock's 52-week low/high is $1.65/$20.50.

China YCT International Group, Inc. (CYIG)

Buzz Stocks, Breaking Bulls, PennyStockCrowd, Marquee Penny Stocks, Penny Stock Rumble, PennyStocksV2, SquawkBoxStocks, Penny Pick Finders, TerrificPennyStocks, AwesomeStocks, PennyStocks24, Chatter Box Stocks, MyBestStockAlerts, and Planet Pennies reported previously on China YCT International Group, Inc. (CYIG), and we also report on the Company, here at the QualityStocks Daily Newsletter.

A diversified company, China YCT International Group, Inc is a developer, manufacturer, and distributor of traditional Chinese medicines (TCM). The Company involves in the business of developing, manufacturing, and selling medicine, developing acer truncatum bunge planting bases and manufacturing and selling the seed oil, and distributing healthcare supplement products manufactured by a third party. OTCQB-listed, China YCT International Group is based in Sishui County, Shandong Province, China.

China YCT engages in developing, manufacturing, and selling its own TCM’s made chiefly from ginseng extract, manufacturing and distributing acertruncatumbunge seed oils, and distributing the aforementioned health care supplement products in China.

In May 2017 of this year, the Company announced that it signed an agreement to purchase the Acer Truncatum business from Shandong YCT Group Co. Ltd. The expectation is that this new business will boost sales by a billion U.S. dollars for China YCT in the next 5 years.

Acer Truncatum is a type of maple. It has 300 species around the world. The Acer Truncatum oil contains 5.8 percent of nervonic acid. Acer Truncatum is contained in plants, and nervonic acid can undergo extraction from these very economically.

Acer Truncatum is only available in China. After more than 40 years’ research and experiments, the Chinese government approved Acer Truncatum oil as general wood food oil, which can be used as a general food oil, such as soybean, corn, olive, and also other food oils.

This week, China YCT International Group announced its financial results for the three and six months ended September 30, 2017. Total Revenues grew by 19.6 percent year-over-year to $13.87 million. The Company had increases in sales of healthcare products and Huoliyuan capsules for the three months ended September 30, 2017.

Overall Gross Margin was 36.5 percent for the three months ended September 30, 2017. This is in comparison to 39.5 percent for the same period of the prior fiscal year. Net Income attributable to China YCT was $2.24 million, or $0.08 per share, for the three months ended September 30, 2017, versus $2.00 million, or $0.07 per share, for the same period of the prior fiscal year.

China YCT International Group, Inc. (CYIG), closed Thursday's trading session at $0.44, even for the day. The average volume for the last 60 days is 2,251 and the stock's 52-week low/high is $0.046/$0.70.

Bravada Gold Corp. (BGAVF)

Real Pennies and Gold Investment Letter reported previously on Bravada Gold Corp. (BGAVF), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Bravada Gold Corp. is a Nevada-focused exploration and development company. The Company has a large portfolio of high-quality properties. These properties cover a range of development stages - from early-stage exploration to advanced-stage exploration and pre-development. Listed on the OTC Markets Group’s OTCQB, Bravada Gold has its head office in Vancouver, British Columbia.

Bravada Gold explores for precious metals in well-established gold trends in one of the world's best gold jurisdictions. Currently, five of its Nevada properties are being funded by partners. In total this includes earn-in work expenditures of up to $6.5 million and payments to Bravada Gold of up to +$3.0 million in cash and shares.

Bravada Gold retains residual working or royalty interests.
For 2017, the Company says that mine permitting continues on its Shoshone Pediment project. Bravada holds a royalty on eventual barite production.

Pertaining to its Wind Mountain project, Bravada Gold’s plan is to drill-test for high-grade “Hishikari-type” gold/silver vein mineralization beneath the existing disseminated resource at Wind Mountain. Regarding the SF property, the Company plans to drill-test for high-grade “Carlin-type” gold mineralization at the SF property.

Concerning the North Lone Mountain and South Lone Mountain projects, plans have not been finalized for Bravada’s two claim groups. However, Nevada Zinc continues to expand the footprint of zinc mineralization on its claims towards Bravada’s South Lone Mountain claims. Should Nevada Zinc complete the purchase of these claims, Bravada Gold will retain a royalty on base and precious metals.

In May of this year, Bravada Gold announced that it received notice that a third-phase drilling program is underway at its Baxter Low-sulfidation gold property in the Walker Lane Gold trend in Nevada. Kinross Gold U.S.A., Inc. plans to drill 8 to 12 reverse-circulation (R.C.) holes for roughly 2,600 meters. Kinross Gold U.S.A. is a wholly-owned subsidiary of Kinross Gold Corp.

The Baxter property comprises 240 unpatented lode claims (approximately 1,940 hectares) in the Walker Lane Gold trend of western Nevada. Bravada Gold previously demonstrated widespread low-sulfidation gold and silver mineralization at surface and in relatively shallow reverse-circulation drill holes at a number of target areas.

Bravada Gold Corp. (BGAVF), closed Thursday's trading session at $0.09, up 16.73%, on 39,500 volume with 6 trades. The average volume for the last 60 days is 19,879 and the stock's 52-week low/high is $0.0732/$0.2567.

graphic

The QualityStocks
Company Corner

graphic
graphic

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.09, up 12.50%, on 23,076 volume with 4 trades. The stock’s average daily volume over the past 60 days is 8,616 and its 52-week low/high is $0.0001/$0.62.

Algae Dynamics Corp (ADYNF) today announced that it and the University of Western Ontario have been awarded C$400,000 in project funding from Mitacs, a Canadian not-for-profit organization committed to supporting research-based innovation. The funds will be used to support the previously announced research agreement by the Company and University of Western Ontario to investigate the role of cannabis-derived phytocannabinoid formulations for the development of novel mental health pharmacotherapies.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Announces C$400,000 Research Grant from Mitacs To Support Cannabis Research With University Of Western Ontario

Algae Dynamics Corp Secures Us $250,000 Investment from Teewinot Life Sciences Corporation

Algae Dynamics Corp Enters Into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products; Accelerates Go-to-Market Strategy

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.049, up 4.26%, on 178,024 volume with 20 trades. The stock’s average daily volume over the past 60 days is 146,623 and its 52-week low/high is $0.003/$0.33.

Skinvisible, Inc. (SKVI) today announces the formation of its Ovation Science, Inc. subsidiary, and the company's definitive license agreement with Lighthouse Strategies, LLC ("Lighthouse"). Per the agreement via Ovation, Lighthouse has exclusive use of Ovation's patented topical and transdermal formulations for select USA markets.

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

New Skinvisible, Inc. (SKVI) Subsidiary Signs Exclusive License Agreement to Distribute Its Topical Cannabis Products in the USA

Skinvisible, Inc. (SKVI) Engages NetworkNewsWire for Corporate Communications Solutions

Skinvisible, Inc. (SKVI) is “One to Watch”

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.0623, up 10.95%, on 7,784,407 volume with 485 trades. The stock’s average daily volume over the past 60 days is 2,972,559, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding Inc. (POTN) announced today, it’s wholly owned subsidiary, Diamond CBD, Inc., has reported its revenues for October. With nearly $1.7 million generated, the Company’s sales exceeded September’s revenues by 42%.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding, Inc. Reports Revenues of $1,694,788 for October, Surpassing September Results by over Half a Million Dollars

PotNetwork Subsidiary Diamond CBD to Exhibit at the 6th Annual Las Vegas MJBizCon Event

PotNetwork Holding, Inc. Announces Distribution Partnership for Easy Grinder™

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.76552, up 2.51%, on 102,730 volume with 44 trades. The stock’s average daily volume over the past 60 days is 108,226 and its 52-week low/high is $0.165/$2.119.

MGX Minerals Inc. (MGXMF) is pleased to report that joint venture partner Power Metals Corp. (“Power Metals”) is nearing completion of the 5,000 metre drill program at Case Lake Lithium.  Forty-four holes have been completed to date.  The program has been extended and five more shallow holes are planned for a total of 49 drill holes (See Figure 2 below).

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Announces Case Lake Lithium Project Drilling Nears Completion

MGX Minerals Initiates Geophysical Survey at Utah Petrolithium Project, Blueberry Unit, Paradox Basin

MGX Minerals Engineering Partner PurLucid Awarded C$8.2M to Manufacture and Deploy Wastewater Treatment Systems Central to MGXs Petrolithium Recovery Process

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.5284, off by 2.15%, on 1,173,797 volume with 602 trades. The stock’s average daily volume over the past 60 days is 708,757, and its 52-week low/high is $0.09/$0.72.

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today it will present at the Biopharma Forum on 'Cannabis-Based Science & Medicine' conference on Thursday, November 30th and Friday, December 1st, 2017 in Denver, CO.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed to Present at Cannabis-Based Science & Medicine Conference

NetworkNewsWire Announces Publication Featuring Innovative Approach to Cannabis R&D

NetworkNewsWire Announces Publication that Highlights Big Pharma's Increasing Interest in Cannabis Biotech Companies

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.471, off by 4.66%, on 28,404 volume with 25 trades. The stock’s average daily volume over the past 60 days is 108,824 and its 52-week low/high is $0.40/$2.75.

"We are excited about the Amazon launch for Singles Day, 11/11/2017. Guanggun Jie which translated literally means 'Single Sticks' Holiday' is an entertaining festival widespread among young Mainland Chinese people, to celebrate being single. This festival has become one the largest offline and online shopping days in the world, and as it has morphed into a global shopping holiday in the last several years; therefore, we thought it was the perfect day to launch with Amazon.com in advance of the holidays," said Warren Wang, CEO of ChineseInvestors.com (CIIX).

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

Updated: ChineseInvestors.com, Inc. Announces That its Subsidiary ChineseHempOil.com, Inc. Launched its OptHemp Product Line on Amazon for Singles Day 2017

ChineseInvestors.com, Inc. Announces that its Subsidiary ChineseHempOil.com, Inc. Launched its OptHemp Product Line on Amazon for Singles Day 2017

NetworkNewsBreaks – ChineseInvestors.com, Inc.’s (CIIX) Investor Relations Division Generates Substantial Revenues

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.02, even for the day, on 919,048 volume with 74 trades. The stock’s average daily volume over the past 60 days is 3,103,139, and its 52-week low/high is $0.009/$0.04.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. continues to make significant headway with Pegasus Fintech, Inc. on their collaboration in the development of a cryptocurrency token for the cannabis industry.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout’s MoneyTrac Technology, Inc. and Strategic Partner Pegasus Fintech, Inc. Move Closer to Launch of their Regulatory Complaint Token Offering for the Cannabis Industry

Global Payout’s Subsidiary, MoneyTrac Technology Inc. Explores Partnerships with Compliance Firms in the Cannabis Banking Sector

Global Payout’s MoneyTrac Technology, Inc. Heads to MJ Business Conference in Las Vegas

AV1 Group, Inc. (AVOP)

The QualityStocks Daily Newsletter would like to spotlight AV1 Group, Inc. (AVOP). Today, AV1 Group, Inc. closed trading at $0.0379, off by 4.77%, on 164,741 volume with 16 trades. The stock’s average daily volume over the past 60 days is 218,985 and its 52-week low/high is $0.017/$0.3499.

AV1 Group, Inc. (AVOP), an investment and holding company that owns diversified businesses in some of the world's largest and fastest growing markets including cannabis related technologies, grow houses and cultivation, and e-commerce businesses positioned for exponential growth, announces it has engaged the corporate communications expertise of NetworkNewsWire.

AV1 Group, Inc. (AVOP), is a publicly traded investment and holding company established to identify, secure and monetize emerging growth companies in a number of sectors that include cannabis related technologies, grow houses and cultivation, and e-commerce businesses positioned for exponential growth. After identifying businesses displaying revolutionary concepts able to develop a substantial footprint in high-growth markets, the business model followed calls for incubating and supporting the best opportunities.

The company seeks to discover inspired entrepreneurs with innovative ideas that are poised for significant revenue generation. Management expertise can be seen in the development of embryonic-stage subsidiaries as the company brings a spectrum of backgrounds to the table with a significant resource of knowledge and experience to every venture. AV1 Group explores every opportunity to help each sector exceed its revenue goals while building close, active working relationships as it prepares each respective division to be a robust competitor within the various chosen markets.

AV1 Group companies include:

  • XFIRESmartSystems.com – Intelligent lighting solutions and wireless access for many different applications.
  • VaporHighUSA.com – Over 800 vaping products; bitcoin payments accepted.
  • DentalCannatizer.com – Revolutionary dual jet dental water jet integrates hemp oil infusing.
  • IntelligentLightingCorp.com – Comprehensive, energy-efficient lighting solutions.
  • CannaLighting.com – Wholly owned subsidiary building strategic relationships in the LED sector to provide solutions for grow houses and cultivation centers.
  • MJIQ – First, comprehensive, enterprise-grade integrated software suite being developed for the legal cannabis industry.
  • Hemptory.com – Engaging online destination for all hemp and cannabis related products and services.
  • Lawster.com – Puts consumers and small businesses in contact with legal services and service providers.
  • MJTestLabs.com – Under development website will serve cannabis dispensaries, laboratories and industry affiliates.

AV1 Group's business model delivers an advantage with internally-created projects that are poised for revenue generation and a cross-company revenue platform that enables the company to incubate and foster growth in early-stage subsidiaries under one umbrella. Disclaimer

AV1 Group, Inc. Blog

AV1 Group, Inc. News:

AV1 Group, Inc. (AVOP) Engages NetworkNewsWire for Corporate Communications Solutions

AV1 Group Announces Pilot for SMART transition of a Major Michigan City for $5.5 Million

AV1 Group, Inc. (AVOP) is “One to Watch”

HighCom Global Security, Inc. (HCGS)

The QualityStocks Daily Newsletter would like to spotlight HighCom Global Security, Inc. (HCGS). Today, HighCom Global Security, Inc. closed trading at $0.0141, off by 29.50%, on 210,000 volume with 6 trade. The stock’s average daily volume over the past 60 days is 55,066 and its 52-week low/high is $0.006/$0.10.

HighCom Global Security, Inc. (HCGS) is pleased to announce that it has received confirmation from the OTC Markets that HighCom Global Security has been accepted and will be upgraded from the OTC Pink sheets to the OTC-QB Venture Marketplace.

HighCom Global Security, Inc. (HCGS) is a manufacturer and distributor of protective products for military and law enforcement personnel. The Corporation operates under two segments, BlastGard Defense Group and Highcom Security.

BlastGard is a blast mitigation specialist with proprietary material proven to effectively mitigate blasts and suppress fires resulting from explosions. The company's patented BlastWrap® technology acts as a "virtual tent" to effectively mitigate blast effects and suppress post-blast fires. This unique technology works by triggering physical and chemical processes to dissipate blast energy, thereby reducing the aftermath of acoustic and shock waves, peak overpressure, reflected peak overpressure, impulse and afterburn. The remaining, significantly reduced energy is transmitted at a slower, more sustainable level. Notably, BlastWrap does not dispense chemical extinguishants; uses neither alarms, sensors, nor an activation system; and is nontoxic and ecologically friendly.

Similarly, the company's BlastGard MTR trash receptacles dramatically reduce lethal threats posed by the detonation of an improvised explosive device (IED). Equipped with Triple Wall Technology, BlastGard MTR mitigates primary fragments, secondary fragments, mechanical effects (shock/blast pressure) and thermal effects (contact and radiation burn) from the fireball, after-burn and resultant post-blast fires.

BlastGard's primary market focus lies on providing blast effects mitigation solutions for customers operating in the commercial sector, military, law enforcement and government agencies. With a vision of being recognized as the leading provider of environmentally responsible solutions to protect lives and structures from the hazards associated with fire and explosions, the company is capable of addressing a wide array of industry applications spanning from fire suppression for naval vessels and merchant ships to protection of buildings against vehicle bombs.

This vision is supported by the ban of Halon extinguishing agents, as outlined in the Montreal protocol, which effectively establishes BlastWrap® as the only blast and fire suppression means available for most applications, including adaptation for underwater use.

The company's position at the head of the blast suppression market has helped BlastGard attain a number of government awards, including designation of its BlastWrap® product as a Qualified Anti-Terrorism Technology and placement on the "Approved Products List for Homeland Security." This designation was extended in early 2017, meaning that BlastWrap® is approved for use by the Department of Homeland Security under the SAFETY Act until November 2021.

HighCom Security, develops, tests, manufactures and distributes body armor and personal protective equipment, including more than two dozen NIJ (National Institute of Justice) compliant hard and soft armor products. Highcom Security has a 20-year history of producing quality armor with no operational failures and no recalls of its American made products.

Highcom Security was founded in 1997 and has produced close to 1 million pieces of armor for the Global community. The company is ISO 9001:2008 certified and the first company in the world to be BA 9000:2012 certified compliant.

For the past decade, Highcom Security has also been able to offer some of the largest armor manufacturers with private label/OEM hard armor solutions for end use by military and law enforcement agencies globally, a market reach obtained because of the company's reputation for innovative technology, exceptional customer service and superior quality performance. Disclaimer

HighCom Global Security, Inc. Blog

HighCom Global Security, Inc. News:

HighCom Global Security receives OTCQB approval

HighCom Global Security Provides Q2, FH 2017 Financial Update

HighCom Global Security Issues Update on Product Technology Advances

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

StockMarketWatch
(CADC) +265.12%

2.

StockMarketWatch
(MRDN) +87.00%

3.

Penny Stock Titans
(TWOH) +54.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251